Financiado en parte por Amgen, Amgen Inc.
The relationship between Lp(a) and CVD outcomes: a systematic review
Forbes CA, Quek RG, Deshpande S, Worthy G, Wolff R, Stirk L, Kleijnen J, Gandra SR, Djedjos S, Wong ND
Lipids in health and disease · 45 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Amgen
- Empresa
- Amgen Inc.
Según 2 financiadores declarados.
Publicación
- Publicado
- 2016-05-17 · Lipids Health Dis · vol. 15 · número 1 · pág. 95
- Editorial
- BioMed Central
- Citado
- 68 citas · más que el 80% de estudios similares · 1.7× el promedio de su campo
- Referencias
- 106 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Diabetes, Cardiovascular Risks, and Lipoproteins · Atherosclerosis and Cardiovascular Diseases
- Palabras clave
- lipoprotein(a), cardiovascular risk, primary prevention, secondary prevention, cardiovascular events, hazard ratio
- MeSH
- humans, cardiovascular diseases, lipoprotein(a), risk factors, aged
10 autores
- Carol A. Forbes🇬🇧 · autor de correspondenciaKleijnen Systematic Reviews (United Kingdom)
- Ruben G.W. Quek🇺🇸Amgen (United States)
- Sohan Deshpande🇬🇧Kleijnen Systematic Reviews (United Kingdom)
- Gill Worthy🇬🇧Kleijnen Systematic Reviews (United Kingdom)
- Robert F. Wolff🇬🇧Kleijnen Systematic Reviews (United Kingdom)
- Lisa Stirk🇬🇧Kleijnen Systematic Reviews (United Kingdom)
- Jos Kleijnen🇳🇱Maastricht University
- Shravanthi R. Gandra🇺🇸Amgen (United States)
- Stephen Djedjos🇺🇸Amgen (United States)
- Nathan D. Wong🇺🇸University of California, Irvine
Resumen
El texto original del estudio, en el idioma en que se publicó.
Robust associations between lipoprotein(a) [Lp(a)] and CVD outcomes among general populations have been published in previous studies. However, associations in high risk primary prevention and secondary prevention populations are less well defined. In order to investigate this further, a systematic review was performed including prospective studies, which assessed the relationship between Lp(a) and CVD outcomes using multivariable analyses. Additional information was gathered on Lp(a) assays, multivariable modelling and population characteristics. Literature searches from inception up to December 2015 retrieved 2850 records. From these 60 studies were included. Across 39 primary prevention studies in the general population (hazard ratios ranged from 1.16 to 2.97) and seven high risk primary prevention studies (hazard ratios ranged from 1.01 to 3.7), there was evidence of a statistically significant relationship between increased Lp(a) and an increased risk of future CVD. Results in 14 studies of secondary prevention populations were also suggestive of a modest statistically significant relationship (hazard ratios ranged from 0.75 to 3.7).Therefore current evidence would suggest that increased Lp(a) levels are associated with modest increases in the risk of future CVD events in both general and higher risk populations. However, further studies are required to confirm these findings.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.